Glen French, CEO and co-founder of Ashtmatx, shared about Asthmatx success story at B2DG meeting attended by 70+ members. Asthmatx markets the Alair(R) Bronchial Thermoplasty System, designed as treatment for severe asthma. Asthmatx was spun off of Broncus Technologies in 2003. They filed for PMA in 2008 and Alair(R) received FDA approval in April 2010.
Over 300 million people worldwide suffer from asthma, with 20 million of the sufferers residing in USA. Alair targets 2 million of them who suffer from severe asthma which frequently lands them to make emergency room visits and the costs for the medications are staggering.
Asthmatx technology is a minimally invasive bronchial thermoplasty procedure performed under conscious sedation with patients typically returning home the same day. The Alair System delivers thermal energy to the airway wall in a precisely controlled manner to reduce excessive airway smooth muscle. A total of 3 sessions are performed as outpatient therapy. The procedure is designed to decrease the ability of the airways to constrict, thereby reducing the frequency and severity of asthma attacks. French described in details the rigorous studies that were conducted both on canines and on humans and all studies showed remarkable results with reduced levels of exacerbation and better quality of life. Bronchial Thermoplasty System was awarded the 2010 Popular Science “Best of What’s New” Award in the Health category. Effective October 27, 2010 Asthmatx became a wholly-owned subsidiary of Boston Scientific Corp. in a deal with potential value of approximately $450 million.
The presentation was followed by interactive Q&A session.